Navigation Links
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
Date:2/13/2008

12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Hitachi Chemical Diagnostics, ... States launch of the ExoComplete™ 96-Well Plate ... easy system for exosome collection to mRNA purification.  The ... Vesicles ("ISEV") Annual Meeting, April 23 – 26, 2015, ... are intended for research use only of molecular biology ...
(Date:5/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/63gppw/asian_dermatology ) ... Market by Type, by End User - Forecast to 2019" ... Devices market is estimated to grow at a CAGR of ... holds a larger share in the Dermatology devices market around ... The Asian Dermatology Devices market holds a high potential for ...
(Date:5/1/2015)... --  Heska Corporation (NASDAQ: HSKA - ... advanced veterinary diagnostic and other specialty veterinary products , today ... at the 16th Annual B. Riley & Co. Investor Conference ... will be held May 12-14, 2015 at Lowes Hollywood Hotel, ... be available during the day on May 13 for one-on-one ...
Breaking Medicine Technology:New Products for Exosome Isolation to mRNA Purification 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2
... Pharmaceuticals Inc. (NASDAQ: VNDA ) announced ... Vanda,s sublicensor Novartis Pharma AG, has initiated a ... depot) formulation of Fanapt® (iloperidone).  This is a ... and pharmacokinetic profiles of two different long-acting formulations ...
... Noverca – the first and currently only Italian ,Full ... presence in the Health and Wellness Sector . ... has been developed and launched thanks to the long-term ... o verca) and Fatebenefratelli Hospital. Davide ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3EXTENDED HEALTH: Noverca Enters the World of Healthcare 2
(Date:5/4/2015)... MT (PRWEB) May 04, 2015 New ... with Care to Care, LLC to manage outpatient advanced ... help New West Medicare ensure its members are provided ... unnecessary radiation. , Working closely with New West Medicare’s ... promoting the safe use of advanced imaging and provide ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Hinds, Eric Gladen’s documentary Trace Amounts, and Allison Folmar, ... annual autism conference held internationally. , On Sunday, May ... Is recovery from autism possible?" Are you interested in ... You’re In There: winning our war against autism ...
(Date:5/4/2015)... Angeles, California (PRWEB) May 04, 2015 ... a physician practice management firm in Los Angeles ... announced today the patent-pending status of The Sara Soulati ... by Soulati in 2010, is a lifestyle modification and ... in April 2015 to the U. S. Patents and ...
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 Leading ... (CFHI), announced it will be awarding the 2015 Harris ... Knight and Selemawit Ghebrendrias, are the deserving recipients of ... for global service, Harris Llewellyn Wofford. The two recipients ... and passion for global health. , CFHI is ...
Breaking Medicine News(10 mins):Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3
... West Orange, NJ. April 19, 2012. Lauren Strober, ... $554,000 to study factors relating to unemployment in people ... scientist at Kessler Foundation, a major center for cognitive ... in the field of disability employment. She is the ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... don,t work much better for the chronic inflammatory skin ... new study indicates. The researchers found that biologics, ... slightly more effective than a standard drug treatment for ...
... More young cigarette smokers may also be lighting up joints ... a survey of young adults aged 18 to 25, more ... University of California, San Francisco (UCSF), say that,s a big ... prior research, had admitted to using both marijuana and tobacco ...
... April 19 (HealthDay News) -- Men are much more likely than ... discharged from the hospital, a new study finds. Researchers followed ... discharged from the Boston Medical Center to determine if gender played ... to the hospital. The study was published April 18 in ...
... may be possible to render cancer tumours harmless without affecting the ... cancers including breast, lung and bowel cancer. The study was carried ... common chemotherapy drugs used to treat cancer have serious side effects ... but also the cells in the rest of the body. ...
... a new family. But for a family whose baby cries ... the joy may be overshadowed by feelings of helplessness and frustration. ... will impact the parent-child relationship for years to come. Research ... that supports an integrated model of care that is found ...
Cached Medicine News:Health News:Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research 2Health News:New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds 2Health News:New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds 3Health News:Half of Young Cigarette Smokers Also Smoke Pot: Survey 2Health News:Half of Young Cigarette Smokers Also Smoke Pot: Survey 3Health News:After Hospitalization, Men More Likely to Show Up in ER 2Health News:Possible new cancer treatment identified 2Health News:Research shows efficacy of treatment model developed at Women & Infants 2
Sharp tip with cutting edge bent to 45 degrees. Fits 19 gauge or 20 gauge instrument port. 21 gauge x 25 mm. 10 per box....
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
Angled, cannula with 32 gauge tip, 4 mm long, angled 65 degrees 1 mm from tip. 10 per box....
Accommodates either eye. Slotted, malleable aluminum surface. Correct size holes produce ideal pin hole effect. Packaged 50 per box....
Medicine Products: